Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

A study on the therapeutic effects of Topiramate according to the types of migraine

편두통의 형태에 따른 Topiramate의 치료효과 - 무 전조 편두통, 전조 편두통, 그리고 개연적 편두통에 대한 topiramate의 치료 효과 및 치료이후의 임상경과 -

  • Lee, Jun-Hwa (Department of Pediatrics, Masan Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Cho, Kyung-Lae (Department of Pediatrics, Masan Samsung Hospital, Sungkyunkwan University School of Medicine)
  • 이준화 (성균관대학교 의과대학 마산삼성병원 소아과학교실) ;
  • 조경래 (성균관대학교 의과대학 마산삼성병원 소아과학교실)
  • Received : 2009.09.24
  • Accepted : 2010.03.02
  • Published : 2010.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The purpose of this study was to evaluate whether the therapeutic effects of topiramate differ according to the types of migraine. Methods : We recruited 38 children and adolescents with migraine who had been treated with topiramate. The effect of topiramate was evaluated on the basis of the change in the frequency of migraine attacks after treatment. Results : Among patients having migraine with aura, 85.7% showed complete recovery, 1 (7.1%) showed partial recovery, and 1 did not show any recovery. Among patients having migraine without aura, 47.1% showed complete recovery, 29.4 % showed partial recovery, and 23.5% showed no recovery. Among patients suspected with migraine, 1 (20%) showed complete recovery, 1 (20%) showed partial recovery, and 3 (60%) showed no recovery. Conclusion : Our results indicated that topiramate exhibited excellent therapeutic effects for migraine accompanied with aura, and it was effective in migraine without aura. However, the effect of topiramate in patients suspected with migraine was uncertain.

목 적: 편두통의 형태별로 topiramate의 치료효과의 차이를 연구하였다. 방 법: 2005년 1월 1일부터 2008년 6월 30일까지 본 병원 소아청소년과에서 편두통으로 처음 진단하여 topiramate를 처방하여 치료했던 환자 38명을 대상으로 하였다. Topiramate의 치료효과는 최초의 월당 두통발생횟수에 대한 치료 후 월당 두통발생횟수로 완쾌, 개선, 그리고 무효의 세 가지로 판정하였으며 치료 완료 후 1년이 경과한 후의 상태를 완치, 감소, 그리고 지속으로 구분하여 조사하였다. 결 과: 전조 편두통은 84.6%가 완쾌되었고, 1례가 개선, 나머지 1례에서 효과가 없었다. 무 전조 편두통은 47.1%가 완쾌되었고 29.4%가 개선되었으며, 23.5%에서 효과가 없었다. 개연적 편두통의 경우 완쾌와 개선이 각각 20%이었으며 60%에서 효과가 없었다. 이밖에 1례의 무 두통 전조 환자는 완쾌되었고, 소아기 양성 돌발성 현훈은 2례 중 1례는 완쾌를 보였고, 1례는 효과가 없었다. 전체적으로 topiramate 투여 후 평균 57.9%가 쾌유하였고, 18.4%에서 개선되었으며, 그리고 23.7%에서는 효과가 없었다. 편두통의 종류별로는 전조 편두통이 무 전조 편두통에 비해 좋은 치료결과를 보였다. 또한 전조 편두통은 개연적 편두통에 비해서도 치료성적이 좋았다. 그러나 무 전조 편두통과 개연적 편두통은 치료성적의 차이가 없었다. 결 론: Topiramate가 소아 청소년의 전조증세가 있었던 편두통에서 좋은 치료효과를 보였으며, 또한 무 전조 편두통에서도 비교적 좋은 효과를 보였으나 개연적 편두통에서의 그 효과가 불투명하였다. 치료 후의 장기적 경과에서는 대체적으로 관해상태가 지속하였다.

Keywords

References

  1. Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J; Topiramate Pediatric Migraine Study Investigators. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45:1304-12. https://doi.org/10.1111/j.1526-4610.2005.00262.x
  2. Winner P, Gendolla A, Stayer C, Wang S, Yuen E, Battisti WP, Nye JS. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache 2006;46:1503-10. https://doi.org/10.1111/j.1526-4610.2006.00610.x
  3. Hershey AD, Powers SW, Vockell AL, LeCates S, Kabbouche M. Effectiveness of topiramate in the prevention of childhood headaches. Headache 2002;42:810-8. https://doi.org/10.1046/j.1526-4610.2002.02185.x
  4. Kim HS, Whang SJ, Lee JW, Kim TH, Lee JS, Cho KL. The study for therapeutic effects of topiramate on pediatric patients with migraine, especially accompanied by aura. J Korean Child Neuro Soc 2007;15:58-66.
  5. Headache Classification Subcommittee of the International Headache Society(IHS). Classification and diagnostic criteria for headache disorders 2nd edition part one. Cephalagia 2004;24:24-36. https://doi.org/10.1111/j.1468-2982.2004.00895.x
  6. Macedo A, Banos JE, Farre M. Placebo response in the prophylaxis of migraine: a meta-analysis. Eur J Pain 2008;12: 68-75. https://doi.org/10.1016/j.ejpain.2007.03.002
  7. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004;63:2215-24. https://doi.org/10.1212/01.WNL.0000147332.41993.90
  8. Cohen GL. Migraine prophylactic drugs work via ion channels. Med Hypotheses 2005;65:114-22. https://doi.org/10.1016/j.mehy.2005.01.027
  9. Vollono C, Ferraro D, Maleriani M. Antiepileptic drugs in the preventive treatment of migraine in children and adolescents. Drug Dev Res 2007;68:355-9. https://doi.org/10.1002/ddr.20201
  10. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ; TOPMAT-MIG-201(TOP-CHROME) Study Group. Cephalalgia 2007;27:814-23. https://doi.org/10.1111/j.1468-2982.2007.01326.x
  11. Rogawski MA. Common pathophysiologic mechanisms in migraine and epilepsy. Arch Neurol 2008;65:709-14. https://doi.org/10.1001/archneur.65.6.709
  12. Piccinelli P, Borgatti R, Nicoli F, Calcagno P, Bassi MT, Quadrelli M, et al. Relationship between migraine and epilepsy in pediatric age. Headache 2006;46:413-21. https://doi.org/10.1111/j.1526-4610.2006.00373.x
  13. Deprez L, Peeters K, Van Paesschen W, Claeys KG, Claes LR, Suls A, et al. Familial occipitotemporal lobe epilepsy and migraine with visual aura: linkage to chromosome 9q. Neurology 2007;6:1995-2002.
  14. Welch KM. Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention. Headache 2005;45:S25-32. https://doi.org/10.1111/j.1526-4610.2005.4501008.x

Cited by

  1. Effects of Occipital Nerve Block in Pediatric Patients with Occipital Region Headache vol.29, pp.4, 2010, https://doi.org/10.26815/acn.2021.00507